Celcuity Stock Soars 700% in a Year as One Investor's $17 Million Buy Helps Create Top Two Position

Perceptive Advisors purchased 203,881 Celcuity shares in the fourth quarter; the estimated trade value was $16.76 million based on average fourth-quarter pricing. Meanwhile, the quarter-end position value rose by $169.16 million, reflecting both share additions and price movements.

The Motley Fool • Feb 22, 2026

Soleus Adds a Significant Number of Celcuity Shares

Soleus increased its Celcuity stake by 629,398 shares. The firm held over 1.8 million shares at the end of the quarter.

The Motley Fool • Feb 13, 2026

Celcuity Inc. (CELC) Presents at Guggenheim Securities Emerging Outlook: Biotech Summit 2026 Transcript

Celcuity Inc. (CELC) Presents at Guggenheim Securities Emerging Outlook: Biotech Summit 2026 Transcript

Seeking Alpha • Feb 13, 2026

Has Celcuity (CELC) Outpaced Other Medical Stocks This Year?

Here is how Celcuity, Inc. (CELC) and Day One Biopharmaceuticals, Inc. (DAWN) have performed compared to their sector so far this year.

Zacks Investment Research • Feb 13, 2026

Celcuity Appoints Charles Romp to its Board of Directors

MINNEAPOLIS, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced the appointment of Charles (Chip) R. Romp to its Board of Directors.

GlobeNewsWire • Feb 12, 2026

Director Sells 20,000 Celcuity Shares for $2.4 Million Following 933% Share Price Jump

David Dalvey sold 20,000 shares indirectly on Jan. 27, 2026 for a transaction value of ~$2.4 million, at a weighted average price of $120.03 per share. The transaction represented 18.18% of Dalvey's total indirect holdings prior to the sale, reducing his stake from 110,000 to 90,000 shares.

The Motley Fool • Feb 6, 2026

Celcuity to Present at Upcoming Guggenheim Emerging Outlook: Biotech Summit 2026

MINNEAPOLIS, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced its participation in the Guggenheim Emerging Outlook: Biotech Summit 2026 to be held in New York, New York on February 11-12, 2026.

GlobeNewsWire • Feb 4, 2026

These 20 stocks are strong choices for momentum investors

“Big mo” is an “eternal feature” of financial markets worldwide.

Market Watch • Jan 22, 2026

Celcuity Announces FDA Acceptance of New Drug Application for Gedatolisib in HR+/HER2-/PIK3CA Wild-Type Advanced Breast Cancer

FDA grants Priority Review and assigns a PDUFA goal date of July 17, 2026 MINNEAPOLIS, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that the U.S. Food and Drug Administration (“FDA”) has accepted for filing its New Drug Application (“NDA”) for gedatolisib in hormone receptor positive (“HR+”), human epidermal growth factor receptor 2 negative (“HER2-”), PIK3CA wild-type advanced breast cancer (“ABC”). The FDA granted Priority Review and assigned a Prescription Drug User Fee Act (“PDUFA”) goal date of July 17, 2026.

GlobeNewsWire • Jan 20, 2026

Celcuity Stock Up 677% in 6 Months: What's Behind This Huge Increase?

CELC shares surge as NDA filing and strong phase III data boost optimism around gedatolisib's potential.

Zacks Investment Research • Jan 6, 2026